Amgen Inc. vs ByteDance Ltd.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and ByteDance Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating ByteDance Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and ByteDance Ltd. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $186.0B for ByteDance Ltd., while their respective market capitalizations stand at $153.0B and $300.0B. Amgen Inc. is headquartered in United States and ByteDance Ltd. operates from China, and those different home markets shape how each company competes.

Amgen Inc.: A Japanese brewery kept Amgen alive. The upfront payment kept Amgen's laboratory lights on. Five years later, EPO became the first blockbuster drug in biotechnology history. The Kirin deal was not charity; it was a calculated exchange of geographic rights for survival capital. Without it, there might be no Amgen. The FTC sued to block the deal, arguing that Amgen could use its portfolio rebate structures to foreclose competing drugs from formularies. The companies won in court and closed the transaction. The companies won. The acquisition closed. It was the most expensive biotech deal of the year and among the largest in a decade, financed primarily with debt that raised Amgen's leverage ratio significantly. Thousand Oaks, California, 1980. In 1983, scientist Fu-Kuen Lin cloned the gene for erythropoietin, the hormone that signals bone marrow to produce red blood cells. Chemotherapy destroys bone marrow's ability to produce those cells, leaving cancer patients severely anemic and requiring frequent blood transfusions. A synthetic EPO could eliminate the need for transfusions. The FDA approved Epogen in 1989.

ByteDance Ltd.: Facebook users spend 33 minutes. YouTube users spend 74 minutes. ByteDance did not win the attention economy by being slightly better at social media — it built a fundamentally different mechanism for capturing human attention, one that does not require any social connections or prior preferences to begin working. You open the app for the first time and it already knows what you want to watch before you do. The resulting click-through rates consistently outperform the industry average by 20-30%, allowing ByteDance to command premium advertising rates. It was not a social network. It was an algorithm that learned what each individual user wanted to read and delivered it, continuously improving with every click. The product grew explosively. The Musical.ly user base was folded into TikTok in 2018, giving ByteDance an immediate American audience. The algorithm was the same. The platform had reached critical mass faster than any consumer internet product before it. The timing was also, notably, concurrent with the peak of Chinese regulatory pressure on technology companies and escalating U.S. Government scrutiny of TikTok. The global expansion was the execution layer. Whether the timing was coincidence or calculation has never been publicly clarified.

Amgen Inc. and ByteDance Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and ByteDance Ltd..

Amgen Inc. business model: This segment has lower margins than branded biologics but provides volume growth and demonstrates Amgen's commitment to lower-cost medicine access — a narrative that carries important political value during a period of intense congressional scrutiny of drug pricing. The problem is, Amgen's operating margins have typically run between 30% and 35% on a GAAP basis and higher on an adjusted basis, reflecting both the pricing power of its branded biologics and decades of operational refinement. Amgen's financial profile in fiscal year 2024 reflected both the far-reaching impact of the Horizon Therapeutics acquisition and the ongoing pressure from patent expirations and pricing pattern. Ten drugs were subject to the first round of negotiations for 2026 pricing, and Enbrel was among the drugs selected for the second cycle of negotiations targeting 2027. It added Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout — rare disease assets with high per-patient pricing and limited competition.

ByteDance Ltd. business model: This extraordinary financial expansion is not merely a function of user growth, but the direct result of a fundamental structural shift in how digital attention is monetized, transitioning from the legacy social-graph advertising model pioneered by Meta Platforms to an interest-graph algorithmic model that delivers hyper-personalized content and commerce directly to the consumer. The irony is, while digital advertising still accounts for an estimated 75% of ByteDance's total revenue, the company has successfully engineered a closed-loop e-commerce network within Douyin that generated over $70 billion in gross merchandise value (GMV) in 2024, capturing high-margin commission fees, payment processing fees, and live-streaming virtual gift revenues that traditional social media platforms have struggled to replicate. ByteDance's business model relies on a proprietary interest-graph recommendation algorithm that serves highly personalized short-form video content to over 3 billion monthly active users across its applications, monetizing this massive attention pool through digital advertising, e-commerce commissions, live-streaming virtual gifts, and gaming. This segment encompasses in-feed video ads, branded hashtag challenges, top-view placements, and programmatic bidding through ByteDance's proprietary advertising platform, Ocean Engine. In China, Douyin has fundamentally reshaped the traditional e-commerce dominance of Alibaba and JD.com by integrating live-streaming commerce directly into the content feed, allowing creators to sell products smoothly without redirecting users to external applications. ByteDance monetizes this network by taking a commission fee ranging from 2% to 5% on all transactions processed through the platform, alongside payment processing fees and premium placement charges for merchants. This model allows users to purchase virtual currency to send digital gifts to live-streaming creators during broadcasts, with ByteDance retaining approximately 50% of the gross gift value as a platform fee. Meta has invested tens of billions of dollars into replicating TikTok's core mechanics, integrating Reels deeply into the Instagram and Facebook feeds, and successfully using its massive existing user base to drive adoption. Amazon's competitive advantage lies in its unparalleled logistics network, Prime subscription loyalty, and vast product selection, making it the default destination for intentional, need-based shopping. The financial narrative of ByteDance is one of a company that has successfully monetized the underlying attention economy of the mobile internet, using the massive cash flow from its consumer hits to fund the development of the foundational AI and e-commerce infrastructure that powers its future growth. However, the legal battle is expected to cost ByteDance hundreds of millions of dollars in legal fees, and the ongoing uncertainty has already caused a significant decline in US advertiser confidence, with major brands pausing their spending on the platform ahead of potential enforcement actions. In 2024, the European Commission opened formal infringement proceedings against TikTok for alleged violations of the DSA, specifically concerning the protection of minors, the transparency of its recommendation algorithms, and the availability of data for independent researchers. Yet if ByteDance fails to build a reliable, cost-effective fulfillment network in the West, its e-commerce ambitions will be severely constrained, limiting its ability to capture the high-margin commission revenues that drive Douyin's profitability. ByteDance has successfully engineered a content distribution engine that triggers continuous dopamine responses, using a complex array of neural networks to analyze over 400 distinct data points per user session — including watch time, completion rate, scroll velocity, replay frequency, and micro-interactions like likes and shares — to serve a hyper-personalized feed that keeps users engaged for an average of 95.4 minutes per day. This creates a profound switching cost; a user who has trained the TikTok algorithm to understand their specific niche interests over hundreds of hours is highly unlikely to abandon that personalized feed to start over on a competitor's platform, even if the competitor offers similar financial incentives to creators. ByteDance's integration of e-commerce directly into the content feed represents a structural advantage in the digital commerce market. This strategy shifts ByteDance's role from a content distributor to a full-stack commerce operator, allowing the company to capture high-margin commission fees, payment processing revenues, and advertising spend from merchants seeking to promote their products on the platform. Douyin was built from the ground up to use ByteDance's recommendation algorithm, optimizing the user interface for full-screen, vertical video consumption and implementing a highly intuitive swipe mechanic that allowed users to smoothly navigate through an endless feed of personalized content. Every additional product ByteDance sells through Douyin live streams, every additional ad unit TikTok serves on its 95-minute daily session, compounds the revenue from the same fixed base of human attention. The first product was a news aggregation app called Toutiao — Today's Headlines — that used machine learning to personalize a content feed without requiring users to manually select topics or follow specific sources.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of ByteDance Ltd..

Amgen Inc. competitive advantage: Before the first human clinical trial ever tested a biotech-derived protein drug, a small group of venture-backed scientists in a repurposed building in Newbury Park, California, were betting that living cells could be engineered to manufacture medicines at industrial scale — a concept so novel in 1980 that most of Wall Street barely had a vocabulary for it. What makes Amgen genuinely unusual among its peers is the combination of scientific credibility, manufacturing scale, and financial discipline it has maintained over four decades. That singular achievement — turning living cells into life-saving medicines at global scale — is the defining fact of Amgen's half-century existence. Amgen's business model is built on one of the most capital-intensive and intellectually demanding processes in American enterprise: translating fundamental biological discoveries into regulated, manufactured medicines that can be sold at scale. Amgen's manufacturing organization is among the most sophisticated in the biopharma industry, running validated large-scale biologic production at facilities in Thousand Oaks, California; West Greenwich, Rhode Island; Juncos, Puerto Rico; Breda, Netherlands; and Singapore. While Amgen's MariTide program represents a genuine opportunity, it enters a market where Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) have already established billion-dollar revenue bases and massive manufacturing advantages. Amgen's most durable competitive advantage is its manufacturing expertise in large-molecule biologics. Financially, Amgen's scale generates operating use that smaller biotech firms cannot match. EPO had been identified and partially characterized in previous research, but no one had successfully cloned the human EPO gene and produced recombinant EPO protein at meaningful scale. The recombinant DNA tools available in 1980 were primitive by modern standards, but they were sufficient to do something that had never been done: clone human genes, insert them into bacterial or mammalian cell cultures, and produce therapeutic proteins at commercial scale.

ByteDance Ltd. competitive advantage: This segment is driven by the rapid scaling of TikTok Shop in international markets and the mature, closed-loop e-commerce ecosystem of Douyin in China. The business model's greatest strength is its network effect; as more users engage with the platform, the algorithm collects more data, improving the accuracy of content and ad recommendations, which in turn attracts more users and advertisers. The company's competitive moat is fortified by the technological superiority of its interest-graph recommendation algorithm, which analyzes over 400 distinct telemetry signals per user session to deliver hyper-personalized content, creating astronomical switching costs and a highly predictable, high-margin advertising revenue stream. As the global digital economy consolidates around integrated super-apps and AI-driven commerce ecosystems, ByteDance's unique position allows it to capture value across the entire consumer journey, ensuring that whether a user is seeking entertainment, discovering a new product, or collaborating with colleagues, ByteDance's platforms serve as the indispensable infrastructure for their digital lives. While Instagram Reels has achieved significant scale, it suffers from a structural disadvantage; it is a feature embedded within a broader social media application, whereas TikTok is a dedicated, full-screen, immersive experience optimized exclusively for algorithmic content discovery. ByteDance's advantage lies in its ability to drive impulse purchases and brand awareness through highly engaging, entertaining content, whereas Meta and Alphabet excel in capturing high-intent, search-driven commercial traffic. The competitive landscape is further complicated by the rise of regional players like Kuaishou in China, which maintains a strong foothold in lower-tier Chinese cities and has successfully developed its own e-commerce and live-streaming ecosystems, and Snapchat, which continues to dominate the augmented reality and youth messaging space in North America and Europe. Despite this intense, multi-front competition, ByteDance maintains a distinct and formidable position through its technological superiority in algorithmic recommendation, the massive cultural and economic scale of its platforms, and the financial independence provided by its private ownership structure. The financial trajectory of ByteDance over the past five years illustrates the profound impact of its transition from a pure advertising network to a comprehensive digital commerce ecosystem. The FY2024 figures demonstrate a resilient, diversified business that has successfully scaled its international e-commerce operations and maintained high growth rates in its domestic advertising market, even as the broader Chinese technology sector faced regulatory crackdowns and macroeconomic slowdowns. The company is grappling with the structural reality of content moderation at an unprecedented scale. The company's competitive advantage is not rooted in the social connections of its users, but in its mastery of machine learning and behavioral telemetry. This network effect is compounded by the sheer scale of ByteDance's content supply chain. By allowing creators to smoothly tag products in their videos and process transactions without redirecting users to an external application, ByteDance has created a closed-loop ecosystem that drastically reduces friction in the consumer purchasing journey. The combination of algorithmic superiority, massive content scale, integrated e-commerce capabilities, and unparalleled financial independence creates a multi-layered moat that ensures ByteDance will remain the central architect of the global short-form video and digital commerce industries for the foreseeable future. By lowering the barrier to entry for merchants, offering subsidized shipping rates, and providing a strong affiliate creator network, ByteDance aims to populate TikTok Shop with millions of diverse products, shifting consumer behavior from intentional, search-based shopping to impulse, discovery-based shopping. This level of automation is impossible to achieve at scale with human creators, giving ByteDance a massive cost and scalability advantage. By lowering the barrier to entry for merchants and providing them with powerful, AI-generated marketing tools, ByteDance aims to populate the TikTok Shop ecosystem with millions of diverse products, shifting consumer behavior from intentional, search-based shopping on Amazon to impulse, discovery-based shopping on TikTok. While Neihan Duanzi achieved moderate success, it was merely a proving ground for Zhang's core vision: the development of a sophisticated recommendation algorithm capable of understanding user intent and serving highly relevant content at scale.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and ByteDance Ltd. each plan to expand from here.

Amgen Inc. growth strategy: But those same drugs carry price tags that have triggered congressional hearings, federal investigations, and public outrage. Amgen generates revenue through four primary mechanisms: branded biologic product sales in the United States, international product sales in Europe and other markets, licensing and royalty income from partnerships, and a rapidly expanding biosimilars portfolio. Key pipeline assets include MariTide (maridebart cafraglutide), an investigational obesity and diabetes drug that targets both GLP-1 receptor agonism and GIP receptor antagonism — a mechanism that could position Amgen to compete directly with Eli Lilly's tirzepatide and Novo Nordisk's semaglutide in the exploding weight loss drug market. The company has also advanced AMG 133 through Phase 2 trials with weight loss data that attracted significant investor attention in 2024 and 2025. The capital investment required to build and validate these facilities — routinely running into hundreds of millions or billions of dollars per site — creates a structural barrier that reinforces Amgen's competitive position. The company has invested in next-generation multiproduct manufacturing facilities that can be adapted to different biologic drug types with shorter reconfiguration times, improving capital efficiency. Capital allocation historically favored a combination of R&D reinvestment, dividend payments (the quarterly dividend reached $2.25 per share in 2024, yielding approximately 3%), and share repurchases. While the United States accounted for approximately 75% of product revenues in 2024, the company has been growing its ex-U.S. Presence, particularly in Europe where biosimilars face more receptive regulatory and market environments than in the U.S. Amgen's European commercial infrastructure, bolstered by its 2013 acquisition of deCODE Genetics in Iceland and longstanding partnerships across major EU markets, provides both revenue diversification and access to genomic research populations that inform drug discovery. Amgen Inc. was established at the dawn of the biotechnology era and has grown to become the archetype of what a successful independent biotech company can achieve. The company is organized into research and development divisions focused on oncology, cardiovascular and metabolic diseases, inflammation, bone health, rare diseases, and neuroscience. Amgen's competitive posture has evolved from a largely defensive stance in the early 2010s — when it was focused primarily on defending Enbrel and Neulasta from biosimilar competition — toward a more aggressive offensive strategy combining pipeline development, strategic acquisitions, and biosimilar market entry. The question of how much revenue Amgen can sustain through the mid-2020s patent cliff cycle while simultaneously growing new franchises defines the company's near-term financial trajectory. Amgen's growth strategy rests on four interdependent pillars that CEO Robert Bradway has consistently articulated to investors since 2020. Tepezza has significant underpenetrated market opportunity — the vast majority of thyroid eye disease patients remain undertreated despite Tepezza's strong clinical evidence — and Amgen has invested heavily in patient identification programs, specialist education, and payer coverage expansion since the acquisition closed. The third pillar is building the biosimilars business into a durable revenue contributor. Amgen has committed to launching biosimilar versions of multiple high-revenue biologics as they lose exclusivity through 2030, using its manufacturing capabilities to achieve cost structures that enable profitable competition at biosimilar price points. The fourth pillar is disciplined financial management — specifically debt reduction from the Horizon acquisition while preserving R&D investment and the dividend. Management has targeted returning to investment-grade credit metrics by 2027, which would restore full capital allocation flexibility including potential smaller bolt-on acquisitions in therapeutic categories where Amgen wants to build pipeline depth. The geographic growth opportunity in emerging markets, particularly China and Japan, where Amgen is building direct commercial presence, represents a longer-term revenue diversification vector. Amgen is attempting to offset this through volume growth in Repatha, Otezla, Tepezza, and biosimilars, while simultaneously advancing pipeline assets in oncology including tarlatamab (AMG 757), a bispecific T-cell engager targeting DLL3 for small cell lung cancer that received FDA accelerated approval in May 2024. Tarlatamab's launch performance will be an important indicator of Amgen's ability to build new oncology franchises beyond its historical reliance on supportive care drugs. Bowes, a partner at the venture firm U.S. Venture Partners, conceived the idea of building a biotech company from the ground up with experienced professional management at its helm rather than waiting for academics to evolve into businesspeople. Rathmann was not a molecular biologist, but he was a scientist with deep industry experience and an intuitive understanding of how to build research organizations. The company's initial scientific strategy was deliberately broad: it would pursue multiple research directions in protein biology simultaneously, betting that some would eventually yield commercial products without pre-committing to any single therapeutic hypothesis. Amgen moved its operations to a leased building in Newbury Park, California (later incorporated into Thousand Oaks), hiring scientists from Caltech, UCLA, and major pharmaceutical companies. This partnership, unconventional in the extreme — a biotechnology company licensing its core technology to a brewery — demonstrated the creative financial pragmatism that would characterize Amgen's management style for decades. The dual-product base gave the company the financial stability to invest in a research pipeline that would take two more decades to produce its next generation of commercially significant medicines.

ByteDance Ltd. growth strategy: TikTok's international advertising business has been scaling rapidly but is still building toward profitability in many markets. The growth is not from user acquisition — the platform already reaches virtually everyone who will use it — but from deepening monetization of existing attention. The company's trajectory changed permanently in June 2016 with the launch of Douyin, a short-form video application built specifically for the Chinese domestic market, followed exactly 15 months later by the international release of TikTok in September 2017. In response, ByteDance has initiated a massive, multi-billion-dollar legal and public relations campaign, while simultaneously accelerating its domestic monetization and expanding its footprint in emerging markets across Latin America, Southeast Asia, and the Middle East to offset potential losses in the North American market. The company employs approximately 150,000 individuals globally, operating a vast network of research and development centers focused on artificial intelligence, computer vision, and natural language processing, investing over $10 billion annually in R&D to maintain its technological superiority in algorithmic recommendation and generative AI. In international markets, TikTok Shop is replicating this model, focusing initially on Southeast Asia, the United Kingdom, and the United States, where it is aggressively subsidizing shipping costs and offering zero-commission periods to acquire merchants and build a solid supply chain. The cultural and economic scale of TikTok, with 1.5 billion monthly active users and an average daily session time of 95.4 minutes, provides the immense liquidity required to fund the company's ambitious technology roadmap, subsidize its e-commerce logistics network, and acquire complementary technologies in the spatial computing and enterprise software sectors. However, YouTube's corporate culture and historical focus on long-form, search-driven content have made it difficult for the company to fully improved its recommendation algorithm for the rapid, high-frequency consumption patterns of short-form video. While TikTok Shop has achieved explosive growth in Southeast Asia and the UK, its expansion in the US has been hampered by logistical challenges, higher customer acquisition costs, and a lack of the solid fulfillment infrastructure that Amazon has spent decades building. The company's ability to continuously iterate its product features, integrate new monetization mechanics, and expand into adjacent markets like local services and enterprise software allows it to capture value across the entire digital value chain, ensuring that whether a consumer is seeking entertainment, discovering a new product, or learning a new skill, ByteDance's platforms remain the primary destination for their digital attention. The irony is, the company's capital allocation strategy is heavily skewed toward long-term infrastructure, talent acquisition, and aggressive market expansion rather than short-term shareholder returns. ByteDance has deployed billions of dollars to acquire complementary technologies, such as the VR headset manufacturer Pico, and to build out its global server infrastructure and content moderation teams. The single most dangerous threat to ByteDance's long-term growth trajectory and market valuation is the unprecedented geopolitical and regulatory crackdown on Chinese technology companies in the United States and the European Union, coupled with the immense financial and operational costs required to maintain a fragmented global data infrastructure. While ByteDance maintains a lead in average session time, the marginal cost of acquiring new users in Western markets has escalated dramatically, compressing the return on investment for its massive marketing expenditures. Competitors like Meta and Alphabet have attempted to replicate this model with Instagram Reels and YouTube Shorts, but they lack the singular, dedicated focus and the historical data advantage that ByteDance has cultivated since the launch of Douyin in 2016. While public platforms are forced to prioritize short-term quarterly earnings and avoid high-risk, capital-intensive projects, ByteDance can invest billions of dollars over a decade into the development of advanced AI models, global server infrastructure, and e-commerce logistics without the pressure of immediate returns. ByteDance's growth strategy is built on three core pillars: expanding the global e-commerce footprint through TikTok Shop, deepening the integration of generative AI to automate content creation and advertising, and diversifying revenue streams into enterprise software and spatial computing. The first pillar, expanding the global e-commerce footprint, involves transitioning TikTok from a pure entertainment platform into a comprehensive discovery commerce engine. ByteDance is investing heavily in building out the logistical infrastructure, payment processing capabilities, and merchant support systems required to support a massive, global e-commerce marketplace. Yet the integration of cross-border e-commerce capabilities, allowing merchants in China to sell directly to consumers in the US and Europe through a simplified fulfillment process, will further accelerate the growth of TikTok Shop and increase the lifetime value of the platform's user base. The second pillar, deepening generative AI integration, focuses on moving beyond traditional video creation tools to provide pattern, automated, and highly personalized content generation capabilities. ByteDance is expanding its Lark collaboration suite, providing enterprise clients with AI-driven productivity tools, automated workflow management, and smooth video communication, creating sticky, long-term contracts that generate recurring revenue. Simultaneously, the company is investing heavily in the Pico VR headset network, developing immersive shopping experiences, virtual concert venues, and interactive educational platforms that position ByteDance as a leader in the spatial computing market. This multi-pronged growth strategy is designed to drive sustainable, long-term revenue growth by increasing the frequency and depth of user engagement across multiple platforms, while simultaneously expanding the total addressable market through enterprise adoption and next-generation hardware. ByteDance's future strategy is anchored in the aggressive expansion of its global e-commerce footprint, the deepening of its generative artificial intelligence capabilities to automate content creation and advertising, and the continuous evolution of its recommendation algorithms to capture user attention across new formats and demographics. ByteDance's roadmap includes the integration of advanced logistics partnerships, the expansion of its affiliate creator network, and the introduction of AI-driven virtual shopping assistants that can guide users through complex purchasing decisions within the app. The company is investing heavily in developing AI models that can automatically generate high-quality, localized video advertisements for merchants, translate live-streaming broadcasts into multiple languages in real-time, and create synthetic digital avatars that can host 24/7 shopping streams without human intervention. The company is also investing heavily in augmented reality (AR) and virtual reality (VR) through its Pico division, aiming to position its hardware and software network as the primary interface for the next iteration of spatial computing. The success of this future strategy depends on ByteDance's ability to manage the complex regulatory landscape surrounding data privacy, artificial intelligence ethics, and international trade. ByteDance's strategy is to lead with high-quality, engaging consumer experiences that naturally introduce users to AI-driven tools and discovery commerce, rather than forcing adoption through enterprise mandates. Recognizing the global potential of the Douyin model, Zhang Yiming made the strategic decision to launch an international version of the application. The launch of TikTok marked the beginning of ByteDance's transformation from a dominant Chinese technology company into a global media powerhouse, setting the stage for the unprecedented growth and geopolitical friction that would define the company's trajectory in the years to come. Toutiao's growth in China was rapid. By 2016, ByteDance applied the same algorithmic approach to short-form video, launching Douyin in China in September 2016. By 2020, TikTok had been downloaded 1 billion times and was generating the kind of cultural moments — viral dances, political mobilizations, product launches — that previously required television networks to orchestrate.

A closer look at the financial trajectory of Amgen Inc. and ByteDance Ltd. rounds out the comparison.

Amgen Inc.: Amgen reported FY2025 total revenues of $36.8 billion, up 10% year over year, and GAAP net income of $7.7 billion. Product sales grew on volume, with eighteen products reaching record annual sales and fourteen exceeding $1 billion. The Horizon acquisition continued to reshape the portfolio, while amortization, impairment charges, pricing pressure, and R&D investment kept GAAP margins below the cleaner non-GAAP picture.

ByteDance Ltd.: ByteDance's 2025 financial picture is unusually split: revenue is estimated at about $186 billion, up roughly 20%, while net profit reportedly fell by more than 70% to roughly $9 billion because the company accelerated spending on AI infrastructure and research. Overseas revenue reportedly grew nearly 50%, pushing international revenue above 30% of total for the first time, while domestic revenue grew about 20%. Those numbers should be treated differently from public-company filings. ByteDance remains private and does not publish audited annual reports, so the revenue and profit figures on this profile are market and media estimates. The strategic signal is still clear: TikTok Shop and overseas monetization are growing fast, but ByteDance is choosing to absorb profit compression to fund AI and platform infrastructure.